Cypherpunk Technologies’ (CYPH) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Cypherpunk Technologies (NASDAQ:CYPH) in a research note issued to investors on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $1.60 target price on the stock.

Several other equities research analysts have also recently issued reports on CYPH. Weiss Ratings raised Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Wall Street Zen raised Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cypherpunk Technologies has a consensus rating of “Hold” and a consensus price target of $1.60.

Cypherpunk Technologies Price Performance

Cypherpunk Technologies stock opened at $1.71 on Thursday. Cypherpunk Technologies has a 1 year low of $0.27 and a 1 year high of $3.70. The firm’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.82. The stock has a market cap of $184.28 million, a P/E ratio of 3.05 and a beta of 0.09.

Cypherpunk Technologies (NASDAQ:CYPH) last issued its earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

Insider Activity at Cypherpunk Technologies

In other Cypherpunk Technologies news, Director Thomas John Dietz sold 20,000 shares of Cypherpunk Technologies stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total value of $34,400.00. Following the completion of the transaction, the director directly owned 132,500 shares of the company’s stock, valued at $227,900. This trade represents a 13.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CYPH. Millennium Management LLC bought a new stake in Cypherpunk Technologies in the fourth quarter worth $37,000. LPL Financial LLC bought a new position in Cypherpunk Technologies during the fourth quarter valued at $38,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at $44,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at $56,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at $59,000. Institutional investors own 30.46% of the company’s stock.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.